The importance of understanding the controls governing commitment and differentiation of hematopoietic stem cells (HSCs) to specific lineages is underscored by the fact that a block in differentiation is a hallmark of acute leukemias. Acute myeloid leukemia (AML) accounts for most acute leukemias in adults. The transcription factor PU.1 regulates nearly every known myeloid gene and is absolutely required for normal myeloid development. PU.1 is expressed in stem cells and up-regulated early during myeloid and lymphoid commitment. The importance of understanding how PU.1 is regulated is emphasized by studies indicating that altered expression of PU.1 can induce changes in hematopoietic lineage development and dysregulation leads to leukemia. Thus, the overall goal of this continuation proposal is to carry on our studies of how PU.1 is regulated. In the next funding period, we plan to continue previous efforts to study how transcription factors regulate PU.1 by binding to the PU.1 upstream regulatory element (URE). In addition, we will extend these studies to the role of proper regulation of PU.1 on HSC function. These studies will further our understanding of commitment of normal hematopoietic precursors to the myeloid lineage. As such, they are relevant to understanding the block in normal myeloid maturation from blasts to mature myeloid cells in AML.

Public Health Relevance

It is critical to understand how hematopoietic stem cells either self-renew or undergo differentiation to mature blood elements, because this process of differentiation is blocked in Acute Myeloid Leukemia (AML), the most common form of acute leukemias in adults. PU.1 is a transcription factor, meaning a gene whose product turns other genes on and off, and the levels of PU.1 are critical in both normal blood development and in leukemia. By studying how PU.1 is expressed in stem cells and other blood cells, we seek to understand basic mechanisms which will aid in our understanding of how leukemia develops, and ultimately for development of novel therapies based on these findings.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL112719-27
Application #
8424261
Study Section
Molecular and Cellular Hematology (MCH)
Program Officer
Thomas, John
Project Start
1986-01-01
Project End
2016-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
27
Fiscal Year
2013
Total Cost
$414,120
Indirect Cost
$176,120
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Aikawa, Yukiko; Yamagata, Kazutsune; Katsumoto, Takuo et al. (2015) Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells. Cancer Sci 106:227-36
Staber, Philipp B; Zhang, Pu; Ye, Min et al. (2014) The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. Blood 124:2391-9
Zhou, J; Wu, J; Li, B et al. (2014) PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. Leukemia 28:1436-48
Di Ruscio, Annalisa; Ebralidze, Alexander K; Benoukraf, Touati et al. (2013) DNMT1-interacting RNAs block gene-specific DNA methylation. Nature 503:371-6
Chen, Leilei; Li, Yan; Lin, Chi Ho et al. (2013) Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 19:209-16
Yong, Kol Jia; Gao, Chong; Lim, Joline S J et al. (2013) Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 368:2266-76